DaVita Inc. Stock - Zacks highlights shares among top growth picks

Zacks Investment Research has named DaVita Inc. stock one of its featured growth ideas for June 17, underscoring solid earnings metrics and a favorable Rank, while the dialysis provider continues to navigate reimbursement and operational challenges.

Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 16:04 UTC. Details in the imprint.

DaVita Inc. (US23918K1088) draws added attention after Zacks Investment Research highlighted the stock as one of its best growth ideas for June 17. The Zacks note points to DaVita’s favorable Rank and earnings profile as screens for potential outperformance.

What Zacks is signaling

Zacks featured DaVita in a June 17 list of "best growth stocks" for investors, citing its Zacks Rank and growth characteristics as key selection criteria. The firm underscores that DaVita shows strong earnings power within the healthcare providers space. The Zacks commentary dated June 17 places DaVita alongside other growth names screened for favorable valuation and momentum factors.

For DaVita, the mention reinforces a narrative of recovering fundamentals after recent reimbursement and cost pressures in the dialysis industry. While Zacks does not change fundamentals, such visibility can shape short-term attention from retail and institutional investors.

Operational backdrop and strategy

Operationally, DaVita continues to focus on efficiency in its US dialysis network and broader value-based care offerings. The company emphasizes managing a multibillion-dollar commercial payor portfolio through its payor partnerships team, which negotiates contracts and reimbursement structures. A recent senior manager posting describes responsibility for a roughly $7 billion book of commercial revenue and a high-growth national value-based care business.

This focus on payor contracting and value-based arrangements is central to DaVita’s effort to stabilize and improve margins. The model aims to align incentives around outcomes and total cost of care, particularly for patients with chronic kidney disease and end-stage renal disease.

How DaVita makes its money

DaVita generates most of its revenue from operating outpatient dialysis centers that provide life-sustaining treatment to patients with end-stage renal disease. The company is paid by Medicare, Medicaid and commercial insurers for each treatment, and increasingly participates in value-based care programs tied to total kidney-care costs.

Where the stock trades today

DaVita Inc. (US23918K1088) shares trade on the New York Stock Exchange under the ticker DVA, recently quoted at about $209.01 as of 06/17/2026, 16:00 UTC in US dollars.

Key facts on DaVita stock

• Company: DaVita Inc.
• ISIN: US23918K1088
• WKN: A1J7KD
• Ticker: DVA
• Venue: NYSE
• Price (as of 06/17/2026, 16:00 UTC): 209.01 USD
• Market cap: 18,000,000,000 USD (as of 06/17/2026)
• Sector / Industry: Health Care / Health Care Providers & Services
• Index membership: S&P 500
• Next earnings date: not officially scheduled

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.